Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues
Grant revenue	$ 275	$ 868	$ 486	$ 1,814
Clinical trial revenue	214		379	762
Contract revenue		8		8
Total revenues	489	876	865	2,584
Cost of revenues	281	764	508	1,660
Gross profit	208	112	357	924
Operating expenses
General and administrative	3,257	649	5,460	1,335
Research and development	1,960	642	3,309	930
Selling and marketing	53	47	109	97
Total operating expenses	5,270	1,338	8,878	2,362
Loss from operations	(5,062)	(1,226)	(8,521)	(1,438)
Other income and (expenses)
Forgiveness of Paycheck Protection Program loan			300
Interest expense	(2)		(1)
Other income, net	54	10	101	10
Total other income and (expenses), net	52	10	400	10
Net loss	$ (5,010)	$ (1,216)	$ (8,121)	$ (1,428)
Basic and diluted net loss per share (in Dollars per share)	$ (0.26)	$ (0.08)	$ (0.44)	$ (0.09)
Basic and diluted weighted average common shares outstanding (in Shares)	19,005,007	15,970,421	18,252,219	15,970,421